PDCD1 and neoplasm: In xenograft-bearing mice treated with antibodies against PD-1, we observed significant enhancement of B4GALNT1 depletion on the tumor-killing effects of anti-PD-1 antibodies (Fig. 9b), indicating that targeting B4GALNT1 may be a valuable auxiliary approach for modifying current immunotherapy (Fig. 9h).